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tor and hospital dean are usually key people pushing for stapler adoption; patients
typically follow surgeon’s advice about stapler; procurement and other hospital
departments have more limited roles; Reimbursement: Stapler is generally reim-
bursed by urban health insurance programs but not by New Rural Cooperative
Medical System (NRCMS). Main concern of NRCMS authorities is maintaining fund
balance; formal Cost Effectiveness Analysis is not presently used by NRCMS au-
thorities. Pilot Cost Effectiveness Analysis Retrospective pilot cost effectiveness
analysis did not broadly demonstrate statistically significant favorable evidence for
stapler. CONCLUSIONS: Doctors’ operation skills should be trained, cost effective-
ness analysis should be continued, as well as the basic medical security system
should be improved in China.
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OBJECTIVES: To assess the payer-rated value of improved pain response, reduced
analgesic medication use and increased overall survival treatment benefit, for pa-
tients with castration-resistant prostate cancer (CRPC).METHODS:We used a con-
venience sample of payers in the US, France and Italy to conduct a telephone
surveywith an accompanyingweb-based questionnaire. The concern of the survey
was the value to payers of a clinically significant pain response. The web-based
questionnaire included nine different treatment/outcome scenarios associated
with adding a second-generation antisense oligonucleotide (ASO) (product X) to
standard of care (SOC) for patients with CRPC. Scenarios varied in terms of the
percentage of patients who experienced a significant pain response with a concur-
rent specified reduction in pain medication use and survival benefit. For each sce-
nario, the respondents rated their likelihood to recommend product X on a scale
ranged from 1 (definitely would not) through 4 (definitely would). We analyzed quan-
titative scenario responses through use of linear regression methods; qualitative
data analysis was limited to simple item summaries. RESULTS:A total of 36 payers
in the U.S., France and Italy completed the survey and questionnaire. The qualita-
tive data from all three regions showed improved survival drove affirmative rec-
ommendations for product X added to SOC. Informants from France and Italy also
consistently ranked improved pain response as an important product attribute.
The informants also said they would like more evidence regarding cost offsets
associated with the improved pain response of product X plus SOC. The regression
modeling was consistent with the qualitative observations. CONCLUSIONS: Cov-
erage recommendations for the medical management of CRPC are primarily based
on the amount of overall survival treatment benefit. In addition, most payers rec-
ognize increased pain response as an important attribute and said evidence of the
cost offsets associated with pain response would aid decision making.
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OBJECTIVES: Overall Survival (OS) has generally been considered the “gold stan-
dard endpoint” for cancer therapies as it can be assessed with precise accuracy.
Due to long follow up periods, however, crossover effects, subsequent therapies
and large trial sizes, OS is becoming a less feasible endpoint. Therefore, there has
been a shift towards the acceptance of surrogate endpoints as determinants of
clinical efficacy for cancer therapies. In Canada, the iJODR conducts health tech-
nology assessments for oncology products and provides funding recommenda-
tions to public payers. This study was conducted to determine the significance of
various endpoints on decision-making by the iJODR.METHODS: Public recommen-
dations of 23 oncology drugs by the iJODR betweenMarch 2007 and December 2010
were reviewed. Recommendations were analyzed according to therapy setting,
primary and secondary endpoints and clinical results. RESULTS: Of the 23 submis-
sions, one was for use in the adjuvant setting, measuring Disease Free Survival
(DFS) as its primary endpoint and received a positive recommendation. Of the 22
drugs indicated for advanced/metastatic disease, primary endpoints were mea-
sured in 12 (55%) through OS, 5 (18%) through Progression Free Survival (PFS) and 6
(27%) through either Response Rates (RR) or Time to Progression (TTP). Secondary
endpoints included OS, PFS, toxicity, RR, TTP, Quality of Life or Rate of Progression.
Of the 12 drugs with OS as a primary endpoint, 7 (58%) showed statistically signif-
icant increases in OS, with 4 (57%) granted a positive recommendation. Of the 5
with no statistically significant OS improvement, 3 (60%) received positive recom-
mendations based on secondary endpoints. Of the 10 drugswith surrogate primary
endpoints, 6 (60%) received positive recommendations. CONCLUSIONS: These
findings suggest that surrogate endpoints are becoming more commonly used in
clinical trials for regulatory approval and accepted as true measures of clinical
efficacy for oncology therapies in Canada’s funding decisions.
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OBJECTIVES: This study describes the real-world healthcare resource utilization
patterns for MPC patients treated by a urologist and/or an oncologist versus urol-
ogist only. METHODS: Health insurance claims (01/1999-02/2009) from 40 self-in-
sured companies across the US were analyzed. Patients with a metastasis diagno-
sis (ICD-9: 196-199) following 2 prostate cancer diagnoses (ICD-9: 185, V10.46)
within 365 days were identified. Patients with other malignant diagnoses were
excluded. Patients were categorized in the ONCO group if they had 1 claim from
an oncologist ( claims from urologist) and the URO group if they had claims only
from urologist (i.e., no claim from an oncologist). Patients were evaluated for che-
motherapy, hormonal agents, corticosteroids, supportive care, and hospitaliza-
tions during both baseline (defined as 365 days prior tometastasis diagnosis [index
date]) and observation periods. RESULTS: A total of 1,661 URO and 1,131 ONCO
patients formed the study population. At baseline, mean age was similar for URO
and ONCO patients (72.3 vs. 72.8 years). During the baseline period, fewer URO
patients received chemotherapy (3.8% vs. 7.3%), hormonal agents (45.1% vs. 63.1%),
and corticosteroids (16.6%vs. 26.5%), compared to theONCOgroup. The same trend
was observed for supportive care therapies (URO vs. ONCO; biphosphonates: 4.8%
vs. 10.5%; opioids: 33.4% vs. 41.8%). The rate of hospitalization at baseline was
similar between groups. During the observation period, 13.4% of URO patients re-
ceived chemotherapy, compared to 38.5% for ONCO patients. Similar differences
were observed for the use of hormonal therapy (52.7% vs. 71.3%), corticosteroids
(36.5% vs. 61.9%), and supportive care therapies (biphosphonates: 18.1% vs. 38.7%;
opioids: 58.7% vs. 68.3%). Fewer URO patients had hospitalizations (62.4% vs. 72.8%)
during the observation period. CONCLUSIONS: The findings from this observa-
tional study may contribute to the understanding of differing healthcare resource
utilization patterns by physician specialty.
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OBJECTIVES: In metastatic prostate cancer (MPC) patients, treatment options in-
clude hormonal therapies, chemotherapy, and radiotherapy. This study quantifies
the real-world healthcare resource utilization of MPC patients.METHODS: Health
insurance claims from 40 self-insured companies across the US (Employer [E]; 01/
1999-02/2009), and from theMedicare 5% ([M]; 1999-2008) databaseswere analyzed.
Patients with a metastasis diagnosis (ICD-9: 196-199) following 2 prostate cancer
diagnoses (ICD-9: 185, V10.46) within 365 days were identified. Patients with other
malignant diagnoses at baseline, defined as 365 days prior to metastasis diagnosis
(index date), were excluded. Patients were evaluated for baseline medical history,
and for chemotherapy, hormonal agents, radiation, and corticosteroids utilization
during both baseline and observation periods. Hospitalization rates and prostate
cancer-related procedures post index datewere also reported. RESULTS: The study
population comprised 11,725 patients (E: 3,227; M: 8,498). Mean age (SD) was 72.8
(10.2) in Employer and 78.1 (7.7) in Medicare. Mean observation period (SD) was 803
(753) days in Employer and 9.2 (8.2) quarters in Medicare. During the baseline pe-
riod, chemotherapy, hormonal agents, radiation therapy, and corticosteroids were
administered to 5%, 52%, 9%, and 21% of Employer, and 2%, 45%, 8%, and 12% of
Medicare patients respectively, whereas these interventions increased to 22%, 55%,
39%, and 46% for Employer, and to 21%, 50%, 33%, and 29% for Medicare during the
observation period. A total of 66% Employer and 79% Medicare patients were hos-
pitalized post index date. Most patients (E: 92%; M: 98%) had prostate cancer-re-
lated procedures, including prostate specific-antigen testing (E: 39%; M: 80%), com-
puterized axial tomography scan (E: 72%; M: 81%), prostate biopsy (E: 47%; M: 54%),
X-ray (E: 11%;M: 64%), bone scan (E: 56%;M: 60%), andmagnetic resonance imaging
scan (E: 35%; M: 37%). CONCLUSIONS: This observational study describes real-
world utilization patterns in patients with advanced prostate cancer.
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OBJECTIVES: Themain objective is to define clusters of patient diagnoses and to use
them to analyze breast cancer health outcomes.METHODS: The NIS records of 2005
were used. Patients diagnosedwith breast cancerwere extracted, and then clusters of
strings of all diagnoses per hospitalization were defined. Logistic regression models
were used to determine the risk of dying from hospitalization associated with each
cluster and ANOVA models were used to evaluate the effect of diagnosis clusters on
length of stay. Time series models were used to fit the data and predict onemonth of
total charges and the number of hospitalizations for each cluster. The analysis was
performed with SAS, SAS Enterprise Guide (EG), SAS Enterprise Miner (EM), and the
SAS Time Series Forecasting System. RESULTS: Four clusterswere found. These clus-
ters had a significant effect on length of stay and in-hospital death. The best time
seriesmodelswere found to be themean, linear trendand log linear trend. The cluster
defined by breast cancer with internal body organ failure was found to be the worst
conditionwith a longer in-hospital stay and ahigher risk of in-hospital death. The one
month predicted values for this cluster were found to be 942 hospitalizations and
about $26million in total charges.CONCLUSIONS:Cluster analysis is a usefulmethod
to studyhealthoutcomes. EnterpriseMiner is aneffective software for cluster analysis
and Data Mining in general.
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